|Application:||Gene expression microarray analysis|
|Number of samples:||208|
|Release date:||Jan 1 2014|
|Last update date:||Jun 1 2018|
|Diseases:||Adenocarcinoma, Carcinoma, Non-Small-Cell Lung|
|Dataset link||Time-course gene expression profiles of gefitinib-sensitive or -resistant lung adenocarcinoma cells stimulated with EGF, in the presence or absence of gefitinib, EGF receptor tyrosine kinase-specific inhibitor|
Gefitinib-resistance cell line (PC9GR) was established derived from lung adenocarcinoma cell line PC9. PC9 cells and PC9GR cells were treated with the four different conditions, control (No treatment), EGF-treatment, gefitinib-treatment, and both gefitinib and EGF-treatment. In each condition, the gene expression was measured at 26 time points during 24 hrs.
Citations per year